Adam Koppel
CIK 1578965 · EVP, Strategy and Bus. Dev. · last filed 2026-04-20
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DRNA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
JOHN HANCOCK TOWER, 200 CLARENDON ST
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KLRA | Director | 22,583,268 | $12.64 | $285.45M | $25.00M | 1 | 2026-04-20 |
| FHTX | Director | — | $2.07 | — | $0 | 4 | 2024-06-28 |
| Cerevel Therapeutics Holdings, Inc. (CERE) Delisted | Director | 65,693,524 | $44.96 | $2.95B | $125.00M | 4 | 2024-06-07 |
| SLDB | Director | 4,034,582 | $5.99 | $24.17M | $4.80M | 13 | 2024-01-12 |
| Aptinyx Inc. (APTX) Delisted | Director | 5,558,425 | $0.06 | $339.1K | $16.40M | 10 | 2022-05-31 |
| Dicerna Pharmaceuticals Inc (DRNA) Delisted | Director | 0 | $38.22 | $0 | -$180.42M | 10 | 2021-12-29 |
| Cerevel Therapeutics Holdings, Inc. (CEREW) Delisted | Director | 60,632,356 | $18.07 | $1.10B | $103.42M | 3 | 2021-06-14 |
| BCLS Acquisition Corp. (BLSA) Delisted | Director | 487,500 | $10.04 | $4.89M | $0 | 1 | 2020-10-26 |
| TREVENA INC (TRVN) Delisted | Director | — | $0.01 | — | $0 | 5 | 2018-05-17 |
| PTCT | Director | 1,083,333 | $60.69 | $65.75M | $18.75M | 5 | 2017-01-05 |
| BIIB | EVP, Strategy and Bus. Dev. | 2,402 | $249.52 | $599.4K | -$189.0K | 7 | 2016-06-07 |
Recent Filings · Page 6 of 7
64 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2016-06-07 | BIIB | Sell (S) | −555 | -$160.9K | EDGAR |
| 2016-06-06 | BIIB | Mixed | +1,109 | -$154.7K | EDGAR |
| 2016-05-19 | TREVENA INC (TRVN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-04-07 | BIIB | Sell (S) | −102 | -$28.1K | EDGAR |
| 2016-02-25 | BIIB | Mixed | +203 | -$25.4K | EDGAR |
| 2016-02-24 | BIIB | Grant (A) | — | $0 | EDGAR |
| 2016-01-06 | PTCT | Grant (A) | — | $0 | EDGAR |
| 2015-06-04 | BIIB | Mixed | +1,532 | -$330.3K | EDGAR |
| 2015-05-21 | TREVENA INC (TRVN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-02-25 | BIIB | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.